Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19

Wang-Da Liu; Chien-Ching Hung; Jann-Tay Wang; Ming-Jui Tsai; Po-Hsien Kuo; Tai-Ling Chao; Szu-Min Hsieh; Wang-Huei Sheng; Yee-Chun Chen; Sui-Yuan Chang; Shan-Chwen Chang

doi:10.1016/j.jfma.2021.04.010

Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19

J Formos Med Assoc. 2021 Dec;120(12):2186-2190. doi: 10.1016/j.jfma.2021.04.010. Epub 2021 Apr 21.

Authors

Affiliations

¹ Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
² Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan.
³ Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
⁴ Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County, Taiwan.
⁵ Department of Internal Medicine, National Taiwan University Hospital Biomedical Park Hospital, Hsinchu, Taiwan.
⁶ Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
⁷ Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
⁸ Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
⁹ Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: changsc@ntu.edu.tw.

Abstract

We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day onset but decreased on 157th day after symptoms.

Keywords: Antiretroviral therapy; Coronavirus; Enzyme-linked immunosorbent assay (ELISA); Plaque reduction assay; Severe acute respiratory syndrome.

Publication types

Case Reports

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
COVID-19*
Enzyme-Linked Immunosorbent Assay
HIV Infections* / complications
Humans
Immunoglobulin G
SARS-CoV-2

Substances

Antibodies, Neutralizing
Antibodies, Viral
Immunoglobulin G